沙美特罗替卡松联合罗红霉素对老年支气管扩张患者肺功能和炎症因子的影响

发布时间：2018-08-25 14:49

【摘要】：目的:观察沙美特罗替卡松联合罗红霉素对老年支气管扩张患者肺功能和炎症因子的影响。方法:将82例老年支气管扩张患者随机均分为观察组和对照组。两组患者均给予适当吸氧、支气管舒张药、祛痰药和止咳药等常规治疗。在此基础上,对照组患者给予罗红霉素分散片0.15 g,口服,每天2次;观察组患者在对照组治疗的基础上给予沙美特罗替卡松粉吸入剂,每天2吸。两组患者疗程均为6个月。观察两组患者治疗前后生活质量评分和呼吸困难评分、肺功能指标[1秒用力呼气容积(FEV1)、FEV1占预计值百分比(FEV1%)、FEV1占用力肺活量比值(FEV1/FVC)]、动脉血气指标{动脉血氧分压[p(O2)]、动脉血二氧化碳分压[p(CO2)]}、炎性因子[白细胞介素(IL)-4、IL-6、IL-10、金属蛋白酶(MMP)-9、超敏C反应蛋白(hs-CRP)]及不良反应发生情况。结果:治疗前两组患者生活质量评分、呼吸困难评分、肺功能指标、动脉血气指标、炎症因子比较,差异均无统计学意义(P0.05)。治疗后两组患者生活质量评分、呼吸困难评分、p(O2)、IL-4、IL-6、MMP-9、hs-CRP均显著低于同组治疗前,且观察组低于对照组;肺功能指标、p(CO2)、IL-10均显著高于同组治疗前,且观察组高于对照组,差异均有统计学意义(P0.05)。两组患者治疗期间均未见明显不良反应发生。结论:沙美特罗替卡松联合罗红霉素可改善老年支气管扩张患者的肺功能,减轻炎症反应,安全性较好。
[Abstract]:Aim: to observe the effects of salmeterol and roxithromycin on pulmonary function and inflammatory factors in elderly patients with bronchiectasis. Methods: 82 old patients with bronchiectasis were randomly divided into observation group and control group. Two groups of patients were given appropriate oxygen inhalation, bronchodiastolic drugs, expectorant and cough medicine routine treatment. On this basis, the patients in the control group were given roxithromycin dispersible tablets 0.15 g orally, twice a day, while the patients in the observation group were given salmeterolticasone powder inhalation 2 times a day on the basis of the treatment in the control group. The course of treatment was 6 months. The scores of quality of life and dyspnea before and after treatment were observed in the two groups. Pulmonary function index [forced expiratory volume (FEV1) in one second, FEV1 / predicted percentage (FEV1%), FEV1 occupied vital capacity ratio (FEV1/FVC)], arterial blood gas index {arterial partial pressure of oxygen [p (O2)], arterial partial pressure of carbon dioxide [p (CO2)]}, inflammatory factor [interleukin (IL) -4IL-6 / IL-10, metalloprotein] Enzyme (MMP)-9, hypersensitive C reactive protein (hs-CRP), and adverse reactions. Results: there was no significant difference in quality of life score, dyspnea score, pulmonary function index, arterial blood gas index and inflammatory factor between the two groups before treatment (P0.05). After treatment, the scores of quality of life (QOL), dyspnea score (P (O2) and IL-6 / MMP-9hs-CRP in the two groups were significantly lower than those in the control group and before treatment, and the lung function index (CO2) IL-10 was significantly higher than that in the same group and the control group, and the level of IL-10 in the observation group was higher than that in the control group, and the level of IL-10 in the observation group was significantly higher than that in the control group. The difference was statistically significant (P0.05). No significant adverse reactions occurred during treatment in both groups. Conclusion: salmeterol combined with roxithromycin can improve pulmonary function and reduce inflammation in elderly patients with bronchiectasis.
【作者单位】：崇州市人民医院呼吸内科;
【分类号】：R562.22

【相似文献】